• Explore /
  • Poster
  • / PAM50 intrinsic subtyping and pathologic responses to neoadjuvant trastuzumab-based chemotherapy in HER2-positive breast cancer.

PAM50 intrinsic subtyping and pathologic responses to neoadjuvant trastuzumab-based chemotherapy in HER2-positive breast cancer.

Abstract Poster

Authors

null

P. Gomez Pardo

Breast Cancer Center, Vall d'Hebron University Hospital, Barcelona, Spain

P. Gomez Pardo , A. Prat , G. Bianchini , M. Pickl , A. Belousov , A. Koehler , V. Semiglazov , W. Eiermann , S. Tjulandin , M. Biakhov , A. Lluch , M. Zambetti , F. Vázquez-Mazón , L. Gianni , J. Baselga

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2011 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer - HER2/ER

Track

Breast Cancer

Sub Track

HER2+

Clinical Trial Registration Number

ISRCTN86043495

Citation

J Clin Oncol 29: 2011 (suppl; abstr 554)

Abstract #

554

Poster Bd #

3D

Abstract Disclosures

Similar Posters

First Author: G. Bianchini

First Author: Emanuela Risi

First Author: Anuradha Belur

First Author: Debu Tripathy